View:

Download DOC

Download PDF

Download XLS

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6 K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

EDAP TMS S.A. Files

Press Release issued on

November 5, 2002 regarding

2002 Q3 Financial Results

EDAP TMS S.A.

Parc Activite La Poudrette Lamartine

4/6 Rue du Dauphine

69120 Vaulx-en-Velin

France

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F .........X........ Form 40-F.................

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ............ No .....X.....

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date :

EDAP TMS S.A.

PHILIPPE CHAUVEAU

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

EDAP TMS S.A. REPORTS 2002 THIRD QUARTER FINANCIAL RESULTS
-- Back-Log of Equipment Orders Reconfirm 2002 Expectations --
-- Continued Improvements in Gross Margins --

Vaulx-en-Velin, France, November 5, 2002-- EDAP TMS S.A. (Nasdaq: EDAP), a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today reported financial results for the third quarter ended September 30, 2002.

Revenue for the third quarter of 2002 was EUR 4.1 million compared to revenue of EUR 5.3 million in the third quarter of 2001. Gross margins, as a percent of sales, improved to 38.3 percent from 33.5 percent in the same quarter a year ago. Net loss from the quarter decreased to EUR 1.6 million, or EUR 0.20 per share, from a net loss of EUR 2.3 million, or EUR 0.30 per share, in the same quarter a year ago.

Revenue for the nine months ended September 30, 2002 was EUR 14.0 million compared to revenue of EUR 17.3 million in the nine months ended September 30, 2001. Gross margins, as a percent of sales, improved to 41.5 percent from 38.1 percent in the same period a year ago. Net loss from the period was EUR 1.6 million, or EUR 0.20 per share, versus net income of EUR 1.0 million, or EUR 0.13 per share, in the same period a year ago. At the end of the nine months ended September 30, 2002 the Company had EUR 17.6 million in cash, or EUR 2.26 per share, and a net book value of EUR 30.8 million, or EUR 3.96 per share.

EDAP TMS's performance is tracking to its expectations and would like to specifically highlight five areas:
· HIFU total revenues to double in 2002 versus 2001;
· Urology devices and services division remains consistent with year-over-year revenues with an increase in the number of machines sold in 2002 versus 2001, offset by a decrease in Prostatron orders;
· Continued increases in gross margins as a percent of sales;
· Continued control over recurring operating expenses; and
· Aggressive management of cash flows.

Philippe Chauveau, EDAP's Chairman and Chief Executive Officer, commented, "The Company's results through the third quarter had seasonally low billings of equipment, however, bookings of new orders for this third quarter remained quite strong. We are pleased with the progress that has been achieved so far this year and look forward to a strong fourth quarter and finish to the year, because we believe that we will meet our projected net operating income due to better margins, controlled operating expenses and cost savings within the organization.

"As we have previously released, our HIFU division has recently sold machines to hospitals in Marseilles, France and Manilla, The Philippines, which will be represented in fourth quarter revenues. Additionally, there are other sales in the pipeline that will be announced upon completion of the sales process. We believe that the focus on growth of our HIFU division, EDAP S.A., validates the realignment of the Company into two separate operating divisions. As approved by Ernst & Young we will report the key numbers of the two separate divisions for the years 2000, 2001, and 2002 with our total financial year 2002 reporting, on form 20-F, in early 2003. This will have no impact on reported consolidated results.

"In the urology devices and services division, we sold an additional eight lithotripsy units during the quarter, which is an increase of EUR 0.2 million in revenues versus the third quarter last year, bringing our year-to-date number of units sold to twenty machines, already equal to the total number of units sold in 2001. This increase in lithotripsy revenue was offset by a decrease of EUR 0.8 million in Prostatron sales and a decrease of EUR 0.6 million in Prostaprobe sales to Urologix, Inc. during the same period. Our lithotripsy service business, as is consistent with the industry, remains flat in 2002.

"During the quarter, the Company continued to make significant progress on increasing gross margins, stringently controlling recurring operating expenses and managing cash flow. This is evidenced by a decrease in recurring operating expenses of 6% or EUR 0.5 million year over year through September 2002. The Company recognized approximately EUR 0.7 million in non-recurring operating expenses primarily related to the creation of the two business divisions and we believe that the Company has appropriately reserved these expenses in the third quarter. Therefore, these expenses should have no further impact on this year's financial results. We view these expenses as an investment in the future of the Company and should be offset by future growth of the businesses.

"Finally, we were very pleased to announce during the quarter that the Company is adding three new members to the board of directors which will bring our total number of independent board members to five," concluded Mr. Chauveau.

EDAP TMS S.A., is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently produces and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU) and the treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company also produces and markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The Company is also developing HIFU for the treatment of certain other types of tumors. For more information, in the U.S., contact EDAP Technomed Inc., the Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission

NOTE: Translated for convenience of the reader to U.S. dollars at the year 2002 average three months noon buying rate of 1 Euro = 0.9827 USD, and year 2001 average three months noon buying rate of 1 Euro = 0.8980 USD.

NOTE: Translated for convenience of the reader to U.S. dollars at the year 2002 average six months noon buying rate of 1 Euro = 0.9294 USD, and year 2001 average three months noon buying rate of 1 Euro = 0.8895 USD.

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 0.9879 USD, on September 30, 2002 and at the noon buying rate of 1 Euro = 0.9856 USD, on June 30, 2002.